Ascendis Pharma A/S ADR (ASND) Stock is Just Right Size-Neither Too Big Nor Too Small
Jefferies raised the price target for the Ascendis Pharma A/S ADR (NASDAQ:ASND) stock to “a Buy”. The rating was released on December 20, 2023, according to finviz. The stock was downgraded by Morgan Stanley, who disclosed in a research note on April 04, 2023, from Overweight to Equal-Weight and set the price objective to $108. […]
With upside potential, Ascendis Pharma A/S ADR (ASND) Stock is well-positioned to grow
Jefferies raised the price target for the Ascendis Pharma A/S ADR (NASDAQ:ASND) stock to “a Buy”. The rating was released on December 20, 2023, according to finviz. The stock was downgraded by Morgan Stanley, who disclosed in a research note on April 04, 2023, from Overweight to Equal-Weight and set the price objective to $108. […]
The high-quality value of Ascendis Pharma A/S ADR (ASND) Stock is hidden beneath the surface
Jefferies raised the price target for the Ascendis Pharma A/S ADR (NASDAQ:ASND) stock to “a Buy”. The rating was released on December 20, 2023, according to finviz. Historical Earnings Surprises and Revenue Forecasts It appears that the average earnings per share estimate for the current quarter (ending in Mar 2023) is $0. This is an […]
What does the future hold for Ascendis Pharma A/S ADR (ASND) Stock?
Jefferies raised the price target for the Ascendis Pharma A/S ADR (NASDAQ:ASND) stock to “a Buy”. The rating was released on December 20, 2023, according to finviz. Historical Earnings Surprises and Revenue Forecasts It appears that the average earnings per share estimate for the current quarter (ending in Mar 2023) is $0. This is an […]